Provider review
Pepti review: GLP-1 pricing and program limits
Pepti’s dated $109 semaglutide offer leaves dose-pricing questions unresolved. Compare the recorded terms, pharmacy disclosures and evidence limitations.
Updated · Editorial standards
In this brief
Pepti advertises compounded injections alongside a broad prescription catalog. Its September 2026 price review recorded $109 a month for semaglutide and $179 for tirzepatide, but an unresolved discrepancy with earlier product data limits how confidently those figures can be used. The distinction between the displayed offer and the unresolved dose pricing is explained below. See the Pepti provider profile for the summary and rating.
The price, as the site renders it
The September 2026 public offer listed injectable semaglutide at $109 and tirzepatide at $179, described as flat across titration doses. The recorded one-time purchase prices were $124 and $249. Those figures do not equal a consistent multiplier of the subscription prices; confirm the total for your selected purchase option. The recorded cancellation terms allowed cancellation at cycle end and a pause of up to 90 days.1
The August catalog also listed oral semaglutide at $249 a month, oral tirzepatide at $399, GLP-1 oral drops at $239, and two low-dose products at $149 and $229. Other recorded listings included BPC-157 at $209, NAD+ at $159–$219, sermorelin and tesamorelin at $189 each, DSIP at $189, PT-141 at $189–$199, and a $199 home blood panel. Those catalog prices were not rechecked in the September update and are not current quotes or treatment recommendations.
Unresolved dose pricing
The August 2026 source records contained an additional, undisplayed dose-price list: semaglutide at $299, $349, $399 and $449; tirzepatide at $349, $399, $449 and $549. Those records conflict with the flat-price offer described on the public pages. An unused price list does not establish what a customer will be charged, and these older values were not rechecked during the September price update.
The September public offer was $109 for semaglutide and $179 for tirzepatide. No completed checkout was used to verify a personal charge. Before paying, request the amount for your prescribed dose, the supply period and the renewal price in writing. Keep the offer and confirmation together so you can compare them if a later bill differs.
The older data could be obsolete; it does not prove a future price increase. The unresolved difference is a reason to obtain a quote, not to assume either price applies. Our price-comparison guide explains how to separate introductory rates, recurring prices and dose-related changes.
Advertised coverage and individual eligibility
The August review found a 36-state list that conflicted with a nationwide claim. By September 1, 2026, the public pages advertised all 50 states and DC and the shorter list was no longer present. That advertisement does not establish your eligibility or the availability of every prescription. Confirm that a clinician can prescribe and the dispensing pharmacy can serve your location; our state-access guide explains the distinction.
When you are actually charged
The reviewed how-it-works page said payment followed prescribing approval, while the refund policy described collection at checkout before review. Get the timing confirmed before entering payment details. The refund policy described a five-to-ten-business-day refund if treatment was declined, no refunds after shipment and no prorated mid-cycle cancellation. These are the recorded terms, not a guarantee of a refund in an individual dispute.
Other catalog products and evidence limits
The August catalog included retatrutide at $399 a month, along with melanotan II and IGF-1 LR3. Their appearance in a commercial catalog does not establish approval, safety or effectiveness, and this review does not recommend them. Our retatrutide evidence guide separates investigational research from an approved treatment option.
The same catalog listed DSIP at $189 a month, a DSIP/BPC-157/CJC-1295 combination at $239, and products labeled semax, selank, synapsin and methylene blue. Calling DSIP a sleep peptide would imply more clinical certainty than this review supports. FDA identifies potential immune-response and peptide-impurity concerns for compounded emideltide (DSIP) and says it lacks sufficient safety information for the proposed route of administration.3 The catalog breadth is not evidence that these products are appropriate treatment choices.
Who is behind it, and who is not named
The August 2026 review recorded Gene Lee as medical director and Laeeq Butt as chief medical officer, with biographies and state-license claims. Those are provider-published credentials, not independent verification by this review. An omitted NPI does not prevent a registry search: CMS says the registry can be searched by provider name, ZIP code or state.4 Confirm the identity and state license of the clinician actually assigned to you. The August pages reviewed did not identify a dispensing pharmacy. The later September provider-directory record names Olympia in a fulfillment policy but lacks its location, while describing the named physician as a content reviewer. These records do not establish who would prescribe or dispense your medication. Request its name and address using the provider checklist. The recorded corporate name was pepti LLC, with a Newark, Delaware address; a corporate address alone does not identify the place where care or dispensing occurs.
The regulatory screen
The August 2026 warning-letter check did not identify a company-name match for Pepti or pepti LLC.2 That dated search result is not FDA approval, proof of compliance or a complete current regulatory history. It also does not verify the unnamed pharmacy or any individual prescription.
What to confirm before paying
The recorded $109 and $179 offers are useful starting points for a quote, but the unresolved dose-pricing records, payment timing and unnamed pharmacy limit the comparison. Before choosing Pepti, get the prescribed product, dispensing pharmacy, supply interval, charge and cancellation terms together in writing. The provider comparison can help identify other services to investigate, but a low advertised price alone does not resolve those questions.
Frequently asked questions
How much does Pepti cost per month?
The September 2026 review recorded $109 for injectable semaglutide and $179 for tirzepatide. Confirm the supply interval, prescribed dose and renewal charge; earlier undisplayed dose-price records remain unresolved.
Is the $109 price reliable?
The September 2026 public offer was $109, while earlier undisplayed semaglutide dose-price records ranged from $299 to $449. Those records do not establish the actual charge. Request a written quote for your prescribed dose and supply interval before paying.
What states does Pepti serve?
By September 1, 2026, the reviewed public pages advertised all 50 states and DC. Confirm current prescribing and pharmacy availability for your location and prescription.
When does Pepti charge you?
The recorded refund policy described payment before clinical review, while the how-it-works page described payment after approval. Ask which applies to your order before paying. The policy described five to ten business days for a refund if treatment was declined.
References
- Pepti (2026). Product catalogue, cost pages and subscription terms. hellopepti.com. https://hellopepti.com/
- U.S. Food and Drug Administration (2026). Warning Letters. FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
- U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (accessed October 28, 2026). FDA. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Centers for Medicare & Medicaid Services (2026). NPI Registry data dissemination: search fields (accessed October 28, 2026). CMS. https://www.cms.gov/regulations-and-guidance/administrative-simplification/nationalprovidentstand/downloads/npi_module4_data_dissemination.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Lighter You review: four-week prices and refund questions
Lighter You’s September 2026 review records public four-week GLP-1 prices, named pharmacy partners and conflicting refund terms.
ReadTrellis Vitality review: $150 semaglutide
Trellis Vitality’s dated review compares GLP-1 plan lengths, starting prices for other programs, named care partners and state-eligibility limits.
ReadVyvron review: $179 every four weeks and what it covers
Vyvron advertises $179 every four weeks for weight management. Compare the longer terms, what the price covers and when a refund may apply.
ReadChoosing insurance for GLP-1 coverage: an open-enrollment checklist
Compare the exact drug, indication, approval rules, pharmacy network and annual costs before choosing a health plan.
ReadIs GLP-1 telehealth legal in my state?
The three questions that actually determine whether a GLP-1 telehealth provider can legally treat you — prescriber licensure, pharmacy licensure, and coverage.
ReadThe Edit review: $259 sema, $349 tirzepatide
The Edit publishes a standing monthly rate and prepay rungs that divide correctly, names its pharmacy and its prescriber, and ships a full Spanish site.
Read